About Adia Nutrition Inc
- Industry: Consumer products
- Exchange: OTC MARKETS
- Country: US
- Website: https://www.adianutrition.com/
Frequently Asked Questions
What is the 52-week range for ADIA?
The 52-week high is $0.2777 and the 52-week low is $0.025.
What is the P/E ratio for ADIA?
The P/E ratio data is currently unavailable.
What is the dividend yield for ADIA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
ROE data is currently unavailable.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
P/B ratio data is currently unavailable.
Latest ADIA News
Adia Med Inc. Announces Adia Labs Expansion of Regenerative Product Line
New research-use products - Adia30M, AdiaClear, and AdiaEXO - give physicians more options in cell count, format, and concentration for investigational studies.Winter Park, Florida--(Newsfile Corp. - September 29, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and physician-supervised investigational research, today announced that its laboratory subsidiary, Adia Labs LLC, has expanded its product portfolio with three new...
Adia Med Inc. Announces Adia Labs Biologic Inventory Now Exceeds $1.5 Million to Meet Rising Demand for the Company's Biological Products
Winter Park, Florida--(Newsfile Corp. - September 22, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and physician-supervised investigational research, today announced that the estimated retail value of biologic inventory at its laboratory division, Adia Labs LLC, now exceeds $1.5 million, driven by accelerating demand for the Company's biologic products as its ongoing clinical studies expand.Management estimates that Adia Labs'...
Adia Med Submits Fifth 2026 Clinical Study to IRB: Osteoarthritis Protocol for One-Time Systemic Treatment
Winter Park, Florida--(Newsfile Corp. - September 15, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company, today announced that its subsidiary, Adia Med of Winter Park, LLC, has submitted a clinical study protocol to an Institutional Review Board for review and approval.The proposed study is designed to evaluate a one-time systemic treatment with AdiaVita, the Company's umbilical cord blood-derived stem cell and exosome product, in adults with osteoarthritis. Participation is...
Nasdaq Shareholder Requirements Just Verified By Adia Med
Winter Park, Florida--(Newsfile Corp. - September 8, 2026) - Nasdaq requires companies seeking an initial listing on the Nasdaq Capital Market to have a sufficiently broad public shareholder base. That distribution test includes:At least 300 round-lot holders;A round-lot holder generally meaning a shareholder holding at least 100 unrestricted shares; andAdia Med has just verified that it currently has 361 round-lot holders, or 61 holders above Nasdaq's 300-holder minimum.Nasdaq Shareholder...